UNSPSC 51292304: Etrabamine

This classification denotes a dopamine antagonist with the molecular formula C8H12N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V55R69267Q, chemically known as 4,5,6,7-tetrahydro-6-(methylamino)benzothiazole but generally known as etrabamine, which bears US NIH Compound Identifier 68895. European Medicines Agency schedules Etrabamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07345MIG.

UNSPSC 51292304 Etrabamine, a Commodity code, captures state and local procurement of pharmaceutical and over-the-counter products, though recent activity shows the code is applied to a broader range of prescription medications, naloxone, and drug-deactivation systems rather than etrabamine specifically. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida, for example, recently issued an IFB for naloxone and drug-deactivation systems to support community health initiatives, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities. Vendors typically must demonstrate cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with authorized wholesalers, provide detailed product information including National Drug Codes and packaging configurations, and carry substantial insurance coverage including commercial general liability.

Recent activity concentrates in Florida and the Upper Midwest, with the Texas Health and Human Services Commission also engaging on prescription-fulfillment strategy through a market-intelligence RFI. Seminole County's IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract included a two-year term with one-year renewal option and potentially FEMA funding. MMCAP's RFP (Solicitation S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson—with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. Texas HHS's RFI (HHS0017013, posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling future state-level competitive solicitation.